{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:57:54Z","timestamp":1785495474798,"version":"3.56.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Health and Family Planning Commission of Peoples Republic of China"},{"name":"Medical Technology Research Center for Health Development","award":["W2012FZ007"],"award-info":[{"award-number":["W2012FZ007"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.lungcan.2018.04.012","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T12:50:04Z","timestamp":1523969404000},"page":"5-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer"],"prefix":"10.1016","volume":"121","author":[{"given":"Keke","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongfa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanxin","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiajuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjun","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketao","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2303-8784","authenticated-orcid":false,"given":"Youxin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.lungcan.2018.04.012_bib0005","doi-asserted-by":"crossref","first-page":"10417","DOI":"10.1158\/0008-5472.CAN-07-1248","article-title":"Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies","volume":"67","author":"Yu","year":"2007","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.lungcan.2018.04.012_bib0010","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1158\/0008-5472.CAN-05-1346","article-title":"An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor","volume":"65","author":"Kobayashi","year":"2005","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2018.04.012_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JTO.0b013e3181913c9f","article-title":"EGFR T790M mutation: a double role in lung cancer cell survival?","volume":"4","author":"Suda","year":"2009","journal-title":"J. Thorac. Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2018.04.012_bib0020","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"Janne","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2018.04.012_bib0025","first-page":"370","article-title":"Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer","volume":"3","author":"Jiang","year":"2014","journal-title":"Transl. Lung Cancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2018.04.012_bib0030","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR-TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.lungcan.2018.04.012_bib0035","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1097\/JTO.0000000000000688","article-title":"Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor","volume":"10","author":"Kim","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2018.04.012_bib0040","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/JTO.0000000000000366","volume":"10","author":"Zinner","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2018.04.012_bib0045","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1586\/14737140.8.5.689","article-title":"Bevacizumab for the treatment of advanced non-small-cell lung cancer","volume":"8","author":"Manegold","year":"2008","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"5","key":"10.1016\/j.lungcan.2018.04.012_bib0050","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1470-2045(05)70155-8","article-title":"Bevacizumab and chemotherapy improves survival in NSCLC","volume":"6","author":"Kerr","year":"2005","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2018.04.012_bib0055","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1186\/s12885-015-1756-1","article-title":"Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014","volume":"15","author":"Takagi","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2018.04.012_bib0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3892\/mco.2017.1282","article-title":"A retrospective study of docetaxel and bevacizumab as a second- or later-line chemotherapy for non-small cell lung cancer","volume":"7","author":"Kurishima","year":"2017","journal-title":"Mol. Clin. Oncol."},{"issue":"Pt. (2)","key":"10.1016\/j.lungcan.2018.04.012_bib0065","doi-asserted-by":"crossref","first-page":"s4613","DOI":"10.1158\/1078-0432.CCR-07-0647","article-title":"Bevacizumab in non small cell lung cancer","volume":"13","author":"Sandler","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 2","key":"10.1016\/j.lungcan.2018.04.012_bib0070","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.3816\/CLC.2007.s.004","article-title":"Chemotherapy and antiangiogenic agents in non-small-cell lung cancer","volume":"8","author":"Horn","year":"2007","journal-title":"Clin. Lung Cancer"},{"issue":"19","key":"10.1016\/j.lungcan.2018.04.012_bib0075","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2014.59.4424","article-title":"BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin\/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer","volume":"33","author":"Zhou","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.lungcan.2018.04.012_bib0080","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2018.04.012_bib0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.lungcan.2018.04.012_bib0090","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2018.04.012_bib0095","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00280-015-2843-3","article-title":"Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents","volume":"76","author":"Shukuya","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.lungcan.2018.04.012_bib0100","first-page":"899","article-title":"Third-line therapy in advanced non-small cell lung cancer","volume":"18","author":"Ying","year":"2013","journal-title":"J. BUON"},{"issue":"2","key":"10.1016\/j.lungcan.2018.04.012_bib0105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2015.02.004","article-title":"Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation","volume":"88","author":"Fukuhara","year":"2015","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2018.04.012_bib0110","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.lungcan.2013.02.021","article-title":"Clinical perspective of afatinib in non-small cell lung cancer","volume":"81","author":"Chen","year":"2013","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2018.04.012_bib0115","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00432-010-0928-2","article-title":"The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients","volume":"137","author":"Sun","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"Pt. (1)","key":"10.1016\/j.lungcan.2018.04.012_bib0120","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/1078-0432.CCR-05-1846","article-title":"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib","volume":"12","author":"Riely","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2018.04.012_bib0125","doi-asserted-by":"crossref","first-page":"8407","DOI":"10.18632\/oncotarget.3511","article-title":"MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma","volume":"6","author":"Chiu","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.lungcan.2018.04.012_bib0130","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/onc.2012.107","article-title":"p14(ARF) Inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway","volume":"32","author":"Ozenne","year":"2013","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.lungcan.2018.04.012_bib0135","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3747\/co.24.3496","article-title":"Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations","volume":"24","author":"Hsu","year":"2017","journal-title":"Curr. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2018.04.012_bib0140","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218303404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218303404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T07:56:27Z","timestamp":1534924587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500218303404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":28,"alternative-id":["S0169500218303404"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.04.012","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}